Active — Not RecruitingNot Applicable

French Registry of First-line Treatment of Acute Promyelocytic Leukemia

France400 participantsStarted 2015-10

Plain-language summary

The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged ≤ 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options, clinical effectiveness and cost-effectiveness, long-term outcome, and short- and long-term toxic effects.

Who can participate

Age range70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Newly-diagnosed APL (either de novo or therapy-related) based on cytologic criteria and confirmed by the presence of the t(15;17) translocation and/or by the detection of the fusion transcript PML/RARα. * Non-high-risk APL (White Blood Count \< 10000/μl at presentation) * Age ≤ 70 years Exclusion Criteria: * Relapsed APL * Newly-diagnosed High-risk APL (White Blood Count \> 10000/μl at presentation) * Age \> 70 years

What they're measuring

Event-free survival

Timeframe: From date of induction until the date of first documented event, assessed up to 60 months

Trial details

NCT IDNCT02938858

SponsorGroupe Francophone des Myelodysplasies

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07

View on ClinicalTrials.gov More Acute Promyelocytic Leukemia trials